A novel ROCK inhibitor: off-target effects of metformin

In drug discovery, most small molecules cannot cross many stages, only a few can become drug candidates. Once the drug molecule is approved and marketed, nontarget effects that are not easily distinguishable from the actual target of the drugs might be evaluated. This situation restricts the treatment. Thus, the discovery of new drugs is a very long and expensive process. In recent years, without developing new drugs, the approach of using different and new target molecules in new indications apart from the indications of licensed drug molecules has gained importance. In this study, using the connectivity map program, it was determined that metformin and tolbutamide used in the treatment of type II diabetes had the potential to inhibit Rho kinase. In the experimental results to confirm this data, it has been shown that metformin and tolbutamide decrease the cell area within 24 h and metformin inhibits the activation of Rho kinase in MCF-7 cells. These results indicate that metformin, which is used in the treatment of type II diabetes, acts as a ROCK inhibitor. Metformin has potential in the treatment of various pathological conditions in which Rho kinase has a role.

Keywords:

Connectivity MAP, Rho kinase, metformin off-target effect, oral antidiabetics,

PDF

___

Albersen M, 2010, EXPERT OPIN EMERG DR, V15, P467, DOI 10.1517/14728214.2010.480973
Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472
Ark M, 2010, APOPTOSIS, V15, P1494, DOI 10.1007/s10495-010-0529-1
Bao B, 2012, CANCER PREV RES, V5, P355, DOI 10.1158/1940-6207.CAPR-11-0299
Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7
Diamanti-Kandarakis E, 2010, ANN NY ACAD SCI, V1205, P192, DOI 10.1111/j.1749-6632.2010.05679.x
Garnock-Jones K, 2014, DRUGS, V74, P2211, DOI 10.1007/s40265-014-0333-2
Jo H, 2014, CELL SIGNAL, V26, P1707, DOI 10.1016/j.cellsig.2014.04.007
Jun HY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178204
Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245
Komers R, 2011, KIDNEY INT, V79, P432, DOI 10.1038/ki.2010.428
Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
Lee DH, 2009, J BIOL CHEM, V284, P11776, DOI 10.1074/jbc.C900014200
Li WG, 2012, DIABETES RES CLIN PR, V96, P187, DOI 10.1016/j.diabres.2011.12.028
Lytvyn Y, 2017, CIRCULATION, V136, P1643, DOI 10.1161/CIRCULATIONAHA.117.030012
Moujaber O, 2020, TRENDS BIOCHEM SCI, V45, P96, DOI 10.1016/j.tibs.2019.11.003
Mueller BK, 2005, NAT REV DRUG DISCOV, V4, P387, DOI 10.1038/nrd1719
Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3
Olson MF, 2008, CURR OPIN CELL BIOL, V20, P242, DOI 10.1016/j.ceb.2008.01.002
OZDEMIR A, 2013, NICHE, V0002, P00015, DOI [DOI 10.5152/niche.2014.153, DOI 10.5152/NICHE.2014.153]
Ozdemir A, 2016, STEROIDS, V109, P29, DOI 10.1016/j.steroids.2016.03.015
Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127
Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128
Saraei P, 2019, CANCER MANAG RES, V11, P3295, DOI 10.2147/CMAR.S200059
Schaafsma D, 2008, EUR J PHARMACOL, V585, P398, DOI 10.1016/j.ejphar.2008.01.056
Simay YD, 2018, CYTOSKELETON, V75, P461, DOI 10.1002/cm.21502
Tang J, 2018, CELL CHEM BIOL, V25, P224, DOI 10.1016/j.chembiol.2017.11.009
Zhang XJ, 2011, CELL MOL BIOL LETT, V16, P279, DOI 10.2478/s11658-011-0006-z